3:25AM
MENU
Advertisement
ChiraGen founder and Carnegie Mellon University researcher Danith Ly (center foreground) recently founded a company that uses an individual's genetic makeup to fight cancer. He was photographed with members of his lab (left to right, Dinithi Perera, Wei-Che Hsieh, Ramesh Batwal, Yookyung Bae and Shivaji A. Thadke) in CMU's Mellon Institute in Oakland on Tuesday, April 10, 2018. (Steve Mellon/Post-Gazette)
2
MORE

Cancer researcher explores new tack

Steve Mellon/Post-Gazette

Cancer researcher explores new tack

Breakthroughs in cancer treatment have resulted from new gene-based treatments, including remission in some cases of childhood leukemia that would otherwise have been fatal.

But the breakthroughs have not been without risk. Seizures, dangerously low blood pressure, raging fevers, even death are among the side effects that have come with high-tech cures. Turns out that, as with conventional chemotherapy, the new treatments are like a light switch — they can be turned on or off only when the medicine is administered or withheld.

Now, Carnegie Mellon University chemistry professor Danith Ly has come up with a way to dial back or accelerate the effects of the treatment — a kind of biological dimmer switch to control the action of the medicine after it has been given. His company, ChiraGen, also is among 10 tenants of the University of Pittsburgh’s LifeX lab space and startup accelerator located in the Strip District.

Advertisement

“He’s clearly passionate about his work,” said Colleen Cassidy, a neurobiologist and assistant director of biopharmaceuticals at LifeX. If he’s successful, “It would be revolutionary.”

LifeX Ventures founder and CEO Dietrich Stephan of Squirrel Hill leads a meeting to discuss the progress of several health and wellness companies Wednesday Nov. 28, 2018, at LifeX on the Southside. This University of Pittsburgh-funded nonprofit, aids research groups that hope to produce new medical therapies that aid patients. (Jessie Wardarski/Post-Gazette)
Kris B. Mamula
LifeX startups face especially long odds in attacking some of medicine's biggest challenges

An open house at LifeX is scheduled for Tuesday. It’s among the events planned for Life Sciences Week 2018: Convergence and Connectivity. Panel discussions, tours and other events are also planned.

ChiraGen is an early, pre-clinical startup and Mr. Ly is the only employee. The company has not yet begun to raise investment money.

Surgery, chemotherapy and radiation are the big guns in cancer care. But in recent years, scientists have created a weapon by genetically souping up the patient’s naturally occurring killer cells in the bloodstream and injecting them into the patient. There, they are meant to hunt down and kill cancer cells.

Advertisement

The procedure harnesses the patient’s own immune system to fight cancer. It has created a market that is expected to generate revenue of $3.9 billion by 2022, according to a forecast by Frost & Sullivan, a San Antonio, Texas-based analytics company.

“Life is so precious”

Mr. Ly was barely 6 in Cambodia when the Khmer Rouge killed his father. The boy and his mother were sent to a collective farm, where they were separated and put to work cultivating rice. Money, private property and the practice of religion were abolished by the government.

At least one-quarter of Cambodia’s population of 7.5 million people died from disease, harsh working conditions or otherwise killed.

“That’s when I learned the value of working hard. That’s when I developed this ideology that life is so precious,” Mr. Ly said. “I survived, I became a stronger person.”

“When I’m in my coffin, I will tell my family I did everything I could to try to make the world a better place to live,” he said.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699

First Published: April 13, 2018, 1:00 p.m.

RELATED
SHOW COMMENTS (0)  
Join the Conversation
Commenting policy | How to Report Abuse
If you would like your comment to be considered for a published letter to the editor, please send it to letters@post-gazette.com. Letters must be under 250 words and may be edited for length and clarity.
Must Read
Partners
Advertisement
ChiraGen founder and Carnegie Mellon University researcher Danith Ly (center foreground) recently founded a company that uses an individual's genetic makeup to fight cancer. He was photographed with members of his lab (left to right, Dinithi Perera, Wei-Che Hsieh, Ramesh Batwal, Yookyung Bae and Shivaji A. Thadke) in CMU's Mellon Institute in Oakland on Tuesday, April 10, 2018. (Steve Mellon/Post-Gazette)  (Steve Mellon/Post-Gazette)
ChiraGen founder and Carnegie Mellon University researcher Danith Ly recently founded a company that uses an individual's genetic makeup to fight cancer. He was photographed in his office in CMU's Mellon Institute in Oakland on Tuesday, April 10, 2018. (Steve Mellon/Post-Gazette)  (Steve Mellon/Post-Gazette)
Steve Mellon/Post-Gazette
Advertisement
LATEST business
Advertisement
TOP
Email a Story